FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022035143> ?p ?o ?g. }

• W2022035143 endingPage "912" @default.
• W2022035143 startingPage "912" @default.
• W2022035143 abstract "Introduction: Industry, clinicians, advocacy, and families have a stake in the success of clinical trials (CTs). Understanding decision-makers’ perceptions of CTs inform efforts to improve recruitment; this is particularly relevant for rare diseases like Duchenne/Becker muscular dystrophy (DBMD). Methods: The study team employed a community-based participatory research approach. US/Canadian parents of children with DBMD who never participated in a CT were recruited for an online survey through Parent Project Muscular Dystrophy and clinics. Participants answered questions about CT preferences and perceived barriers and facilitators. Results: Among the first 99 participants with children age 4–12, 65% wanted their child in a CT, 32% were unsure, and 3% did not. The most endorsed barriers were: possibility of receiving placebo (46% very or moderately true); insufficient information about risks (27%); the possibility of an unsuccessful trial (25%); child may not benefit (25%); and insufficient information about day-to-day requirements (25%). Parents unsure about CT participation endorsed barriers at notably different frequencies than those wanting participation for: insufficient risk information (55% vs. 13%) and child not benefiting (39% vs. 16%). Highly-endorsed facilitators of increased future CT interest were: guaranteed treatment access after CT (82%); having confidence CT would improve DBMD understanding (76%); agreeing with CT goals (75%); treating doctor’s suggestion (72%); perceiving a good researcher reputation (71%). Conclusions: Many facilitators were highly rated for increasing interest in CT participation, supporting adaptive trial design and education and outreach. Parents unsure about participation may have more needs for CT information. The most-endorsed facilitator was treatment access after CT, which is very difficult to achieve. Sponsors should increase outreach through community forums and clinicians to clarify CT processes, personnel, and goals. Introduction: Industry, clinicians, advocacy, and families have a stake in the success of clinical trials (CTs). Understanding decision-makers’ perceptions of CTs inform efforts to improve recruitment; this is particularly relevant for rare diseases like Duchenne/Becker muscular dystrophy (DBMD). Methods: The study team employed a community-based participatory research approach. US/Canadian parents of children with DBMD who never participated in a CT were recruited for an online survey through Parent Project Muscular Dystrophy and clinics. Participants answered questions about CT preferences and perceived barriers and facilitators. Results: Among the first 99 participants with children age 4–12, 65% wanted their child in a CT, 32% were unsure, and 3% did not. The most endorsed barriers were: possibility of receiving placebo (46% very or moderately true); insufficient information about risks (27%); the possibility of an unsuccessful trial (25%); child may not benefit (25%); and insufficient information about day-to-day requirements (25%). Parents unsure about CT participation endorsed barriers at notably different frequencies than those wanting participation for: insufficient risk information (55% vs. 13%) and child not benefiting (39% vs. 16%). Highly-endorsed facilitators of increased future CT interest were: guaranteed treatment access after CT (82%); having confidence CT would improve DBMD understanding (76%); agreeing with CT goals (75%); treating doctor’s suggestion (72%); perceiving a good researcher reputation (71%). Conclusions: Many facilitators were highly rated for increasing interest in CT participation, supporting adaptive trial design and education and outreach. Parents unsure about participation may have more needs for CT information. The most-endorsed facilitator was treatment access after CT, which is very difficult to achieve. Sponsors should increase outreach through community forums and clinicians to clarify CT processes, personnel, and goals." @default.
• W2022035143 created "2016-06-24" @default.
• W2022035143 creator A5011786596 @default.
• W2022035143 creator A5015989394 @default.
• W2022035143 creator A5018840106 @default.
• W2022035143 creator A5024521380 @default.
• W2022035143 creator A5024664136 @default.
• W2022035143 creator A5025697539 @default.
• W2022035143 creator A5031982507 @default.
• W2022035143 creator A5050581697 @default.
• W2022035143 creator A5063179700 @default.
• W2022035143 creator A5088497440 @default.
• W2022035143 date "2014-10-01" @default.
• W2022035143 modified "2023-10-18" @default.
• W2022035143 title "G.P.302" @default.
• W2022035143 doi "https://doi.org/10.1016/j.nmd.2014.06.392" @default.
• W2022035143 hasPublicationYear "2014" @default.
• W2022035143 type Work @default.
• W2022035143 sameAs 2022035143 @default.
• W2022035143 citedByCount "0" @default.
• W2022035143 crossrefType "journal-article" @default.
• W2022035143 hasAuthorship W2022035143A5011786596 @default.
• W2022035143 hasAuthorship W2022035143A5015989394 @default.
• W2022035143 hasAuthorship W2022035143A5018840106 @default.
• W2022035143 hasAuthorship W2022035143A5024521380 @default.
• W2022035143 hasAuthorship W2022035143A5024664136 @default.
• W2022035143 hasAuthorship W2022035143A5025697539 @default.
• W2022035143 hasAuthorship W2022035143A5031982507 @default.
• W2022035143 hasAuthorship W2022035143A5050581697 @default.
• W2022035143 hasAuthorship W2022035143A5063179700 @default.
• W2022035143 hasAuthorship W2022035143A5088497440 @default.
• W2022035143 hasConcept C15744967 @default.
• W2022035143 hasConcept C17744445 @default.
• W2022035143 hasConcept C199539241 @default.
• W2022035143 hasConcept C2776831358 @default.
• W2022035143 hasConcept C2781400479 @default.
• W2022035143 hasConcept C512399662 @default.
• W2022035143 hasConcept C71924100 @default.
• W2022035143 hasConcept C77805123 @default.
• W2022035143 hasConceptScore W2022035143C15744967 @default.
• W2022035143 hasConceptScore W2022035143C17744445 @default.
• W2022035143 hasConceptScore W2022035143C199539241 @default.
• W2022035143 hasConceptScore W2022035143C2776831358 @default.
• W2022035143 hasConceptScore W2022035143C2781400479 @default.
• W2022035143 hasConceptScore W2022035143C512399662 @default.
• W2022035143 hasConceptScore W2022035143C71924100 @default.
• W2022035143 hasConceptScore W2022035143C77805123 @default.
• W2022035143 hasIssue "9-10" @default.
• W2022035143 hasLocation W20220351431 @default.
• W2022035143 hasOpenAccess W2022035143 @default.
• W2022035143 hasPrimaryLocation W20220351431 @default.
• W2022035143 hasRelatedWork W1966956409 @default.
• W2022035143 hasRelatedWork W2130700460 @default.
• W2022035143 hasRelatedWork W2133429384 @default.
• W2022035143 hasRelatedWork W2748952813 @default.
• W2022035143 hasRelatedWork W2891292653 @default.
• W2022035143 hasRelatedWork W2899084033 @default.
• W2022035143 hasRelatedWork W2899802696 @default.
• W2022035143 hasRelatedWork W3013317008 @default.
• W2022035143 hasRelatedWork W3013744818 @default.
• W2022035143 hasRelatedWork W4296078938 @default.
• W2022035143 hasVolume "24" @default.
• W2022035143 isParatext "false" @default.
• W2022035143 isRetracted "false" @default.
• W2022035143 magId "2022035143" @default.
• W2022035143 workType "article" @default.